Cohort profile : the Nordic antireflux surgery cohort (NordASCo)
Author: Maret-Ouda, John; Wahlin, Karl; Artama, Miia; Brusselaers, Nele; Färkkilä, Martti; Lynge, Elsebeth; Mattsson, Fredrik; Pukkala, Eero; Romundstad, Pål; Tryggvadottir, Laufey; Euler-Chelpin, My von; Lagergren, Jesper
Department: Inst för molekylär medicin och kirurgi / Dept of Molecular Medicine and Surgery
View/ Open:
Version of Record (1.043Mb)
Abstract
PURPOSE: To describe a newly created all-Nordic cohort of patients with gastro-oesophageal reflux disease (GORD), entitled the Nordic Antireflux Surgery Cohort (NordASCo), which will be used to compare participants having undergone antireflux surgery with those who have not regarding risk of cancers, other diseases and mortality.
PARTICIPANTS: Included were individuals with a GORD diagnosis recorded in any of the nationwide patient registries in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) in 1964-2014 (with various start and end years in different countries). Data regarding cancer, other diseases and mortality were retrieved from the nationwide registries for cancer, patients and causes of death, respectively.
FINDINGS TO DATE: The NordASCo includes 945 153 individuals with a diagnosis of GORD. Of these, 48 433 (5.1%) have undergone primary antireflux surgery. Median age at primary antireflux surgery ranged from 47 to 52 years in the different countries. The coding practices of GORD seem to have differed between the Nordic countries.
FUTURE PLANS: The NordASCo will initially be used to analyse the risk of developing known or potential GORD-related cancers, that is, tumours of the oesophagus, stomach, larynx, pharynx and lung, and to evaluate the mortality in the short-term and long-term perspectives. Additionally, the cohort will be used to evaluate the risk of non-malignant respiratory conditions that might be caused by aspiration of gastric contents.
PARTICIPANTS: Included were individuals with a GORD diagnosis recorded in any of the nationwide patient registries in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) in 1964-2014 (with various start and end years in different countries). Data regarding cancer, other diseases and mortality were retrieved from the nationwide registries for cancer, patients and causes of death, respectively.
FINDINGS TO DATE: The NordASCo includes 945 153 individuals with a diagnosis of GORD. Of these, 48 433 (5.1%) have undergone primary antireflux surgery. Median age at primary antireflux surgery ranged from 47 to 52 years in the different countries. The coding practices of GORD seem to have differed between the Nordic countries.
FUTURE PLANS: The NordASCo will initially be used to analyse the risk of developing known or potential GORD-related cancers, that is, tumours of the oesophagus, stomach, larynx, pharynx and lung, and to evaluate the mortality in the short-term and long-term perspectives. Additionally, the cohort will be used to evaluate the risk of non-malignant respiratory conditions that might be caused by aspiration of gastric contents.
Institution:
- Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Impact Assessment Unit, Department of Health Protection, National Institute for Health and Welfare, Tampere, Finland.
- Centre for Translational Microbiome Research CTMR, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
- Science For Life Laboratory (SciLifeLab), Stockholm, Sweden.
- Clinic of Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
- Institute for Statistical and Epidemiological Cancer Research, Finnish Cancer Registry, Helsinki, Finland.
- School of Health Sciences, University of Tampere, Tampere, Finland.
- Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
- Icelandic Cancer Registry, Icelandic Cancer Society, Reykjavik, Iceland.
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
- Division of Cancer Studies, King's College London, London, UK.
Citation: BMJ Open. 2017 Jun 8;7(6):e016505.
Citation DOI: 10.1136/bmjopen-2017-016505
Citation PMID: 28600380
Citation ISI: 000406391200230
Publishing journal: BMJ Open
Eprint status: Peer Reviewed
Version: Published
Issue date: 2018-03-06
Sponsorship:
- Swedish Research Council, D0547801
- Swedish Cancer Society, 2015/460
- Nordic Cancer Union, 186058
Rights:
CC BY-NC 4.0
Publication year: 2017
Statistics
Total Visits
Views | |
---|---|
Cohort ... | 290 |
Cohort ...(legacy) | 131 |
Total Visits Per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
Cohort ... | 2 | 30 | 7 | 3 | 0 | 2 | 1 |
File Visits
Views | |
---|---|
BMJ open_publ.pdf | 275 |
BMJ open_publ.pdf(legacy) | 61 |
Top country views
Views | |
---|---|
United States | 166 |
Sweden | 84 |
Germany | 40 |
China | 24 |
France | 9 |
Ireland | 9 |
Austria | 8 |
Finland | 7 |
Russia | 7 |
United Kingdom | 3 |
Top cities views
Views | |
---|---|
Ashburn | 106 |
San Mateo | 25 |
Stockholm | 10 |
Dublin | 9 |
Beijing | 7 |
Umeå | 7 |
Vienna | 7 |
Kiez | 6 |
Moscow | 6 |
Andover | 4 |